Alphabetical Test Section 17182X -hydroxylase deficiencies. In In deficiencies. -hydroxylase β Liquid chromatography tandem tandem chromatography Liquid spectrometrymass (LC/MS/MS) 5 ng/dL sensitivity: Analytical Clinical Background is an androgenic the by both produced In the gonads. cortex and adrenal is activity the compound's males, with compared unimportant, relatively testicular the predominant females, andros- In . and the testosterone tenedione–and is it to which to contribute metabolized–normally dependent of sexually the growth the In women, axillary hair. and pubic androstenedione of concentration with cycle, with the menstrual varies adrenals contributing and the phase. At follicular during the equally andros- ovarian increased mid-cycle, for 70% accounts secretion tenedione overall production. of its production androstenedione Excessive to and contribute cause may in the can occur This virilization. polycystic syndrome, idiopathic and adrenal ovarian hirsutism, neoplasms, and congenital adrenal or to 21-hydroxylase due hyperplasia 17 with an elevated patients hirsute serial concentration, androstenedione monitor useful to are measurements improvement since clinical therapy, the biochemical lags behind typically by months. response Method • • Specimen Requirements serum refrigerated 1 mL 0.25 mL minimum top tube red No additive red top unacceptable SST 25 6-78 5-51 20-75 6-115 50-220 40-190 50-220 35-250 60-285 30-235 12-221 22-225 ng/dL J ClinJ Endocrinol Metab. J Clin Endocrinol Metab. Addison's disease Addison's Idiopathic hirsutism Idiopathic Polycystic ovarian disease ovarian Polycystic Congenital adrenal hyperplasia adrenal Congenital Cushing’s disease Cushing’s Adrenal tumors Adrenal • • • • • • MalesFemales 57-150 7-68 MalesFemales 43-180 17-82 Diagnose hirsutism, polycystic polycystic hirsutism, Diagnose and virilization, disease, ovarian hyperplasia adrenal congenital 18-30 y 18-30 y 31-50 y 51-60 Follicular Midcycle Luteal Postmenopausal Tanner IV-V Tanner Tanner II-III Tanner 1-12 m 1-12 1-4 y 5-9 y y 10-13 y 14-17 Pediatric data from 1991;73:674-686 and 1989;69:1133-1136. Men Women Children Interpretive Information Interpretive Reference Range Reference Clinical Use Androstenedione, LC/MS/MS Androstenedione, •